NR3C2 and infection: Consistent with this premise, we proposed that pharmacologic targeting of either individual MRs (ViroTarget) or of the entire MR protein module that regulates the virus-induced host-cell response (ViroTreat) could mitigate viral replication and infection comorbidity.